Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($8.50) by $8.80, FiscalAI reports. The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.49 million.
Scinai Immunotherapeutics Price Performance
Shares of NASDAQ:SCNI opened at $0.44 on Monday. The business has a 50-day moving average price of $1.28 and a 200 day moving average price of $4.27. The company has a current ratio of 1.56, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $595,350.00, a price-to-earnings ratio of -0.00 and a beta of 2.27. Scinai Immunotherapeutics has a 12-month low of $0.39 and a 12-month high of $13.00.
Shares of Scinai Immunotherapeutics are set to reverse split on the morning of Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, November 18th.
Analyst Ratings Changes
Separately, Weiss Ratings raised shares of Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on SCNI
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects.
Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.
Featured Stories
- Five stocks we like better than Scinai Immunotherapeutics
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
